Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.68 |
| ▸ | TACR3 | P29371 | 15/20 | 0.66 |
| ▸ | TACR2 | P21452 | 14/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.66 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635944 | 0.92 | TACR3 (0.65) | CYP2C9TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL14009547 | 0.90 | TACR3 (0.63) | CYP2C9TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL14009586 | 0.90 | CYP2C9 (0.68) | CYP2C9TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL14009568 | 0.86 | TACR3 (0.65) | CYP2C9TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL5420737 | 0.85 | TACR3 (0.71) | CYP2C9TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL14009548 | 0.84 | TACR3 (0.62) | CYP2C9TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL1581445 | 0.84 | TACR3 (0.69) | CYP2C9TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL1581261 | 0.83 | TACR3 (0.68) | CYP2C9TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL5908992 | 0.83 | TACR3 (0.68) | CYP2C9TACR3TACR2OPRM1TRPV4 | |
| SCHEMBL5909008 | 0.83 | TACR3 (0.68) | CYP2C9TACR3TACR2OPRM1TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| WO-2007018466-A1 | ALKYLPYRIDYL QUINOLINES AS NK3 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287492-A1 | Alkylpyridyl Quinolines as Nk3 Receptor Modulators | ADORA3, KCNA3, TACR1 | CYP2C9 1365/4885TACR3 12/4885TACR2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.